Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children

Virginia Commonwealth University166 enrolled

Overview

The purposes of this study are to identify potential gene and protein markers of aminoglycoside-induced kidney injury in infants, children and adolescents treated with aminoglycoside antibiotics.

Study Type

OBSERVATIONAL

Enrollment

166

Conditions

Infection Renal Dysfunction

Interventions

aminoglycosideDRUG

Aminoglycosides will be administered and monitored as part of the routine standard of care for the subject.

Eligibility

Sex: ALLMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: (1) Hospitalized male and female newborns, infants, children and adolescents (ages birth to 18 years) with a diagnosis of suspected or proven bacterial sepsis, meningitis or other indication necessitating aminoglycoside therapy (2) hospitalized and outpatient newborns, infants, children and adolescents (ages birth to 18 years) who are not receiving aminoglycoside therapy. Exclusion Criteria: (1) Current treatment with inhaled or ophthalmic aminoglycosides (2) Prior treatment with an aminoglycoside within the last 30 days

Locations (2)

University of Lousiville

Louisville, Kentucky, United States

Virginia Commonwealth University

Richmond, Virginia, United States

Outcomes

Primary Outcomes

Indicators of renal injury

Time frame: Pre and post treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.